Navino Pharmaceutical Technology

Navino Pharma is a clinical-stage biopharmaceutical company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics. The company primarily targets metabolic diseases and inflammatory conditions, with a lead program, NVN-01, currently in Phase 2 clinical trials for the treatment of gout and hyperuricemia. Navino leverages its proprietary drug discovery platform to design highly selective molecules with improved safety and efficacy profiles compared to existing standards of care. Founded by industry veterans with expertise in medicinal chemistry, the company aims to address significant unmet medical needs in the global market. The firm's R&D strategy emphasizes the development of Best-in-class drugs by optimizing pharmacokinetic and pharmacodynamic properties. Navino Pharma has successfully secured multiple rounds of venture capital funding to advance its pipeline through clinical development.